×
Integrated Tumor and Immune Cell Multiomic Analyses Predict ICB Response in Advanced Melanoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200165/full/

May 28th, 2020 - Immunoglobulin (Ig) gene rearrangements, expressed tumor mutation burden (TMB), tumor aneuploidy, and pre-existing T- and B-cell immunity may predict response to immune checkpoint blockade (ICB) and subsequent prognosis in patients with advanced melanoma, according to a study (Abstract 10009) presented by Valsamo Anagnostou, MD, PhD, of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at...

Interim Analysis of GAIN-2 Indicates Dose-Dense Chemotherapy Regimens Are Equivalent
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200142/full/

May 28th, 2020 - An interim analysis of the GAIN-2 study in patients with high-risk early-stage breast cancer indicated that the use of neoadjuvant/adjuvant intense, dose-dense epirubicin, nab-paclitaxel, and cyclophosphamide (iddEnPC) and dose-dense, dose-tailored epirubicin/cyclophosphamide followed by dose-dense, dose-tailored docetaxel (dtEC-dtD) were equivalent (Abstract 516).

Locoregional Treatment of Intact Primary Tumor Does Not Improve Survival, HRQoL in Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200210/full/

May 30th, 2020 - Early initiation of locoregional treatment (LRT) of an intact primary tumor (IPT) in women with de novo stage IV metastatic breast cancer does not appear to prolong survival or improve health-related quality of life (HRQoL) compared with systemic therapy alone, according to a new study (Abstract LBA2). Seema A. Khan, MD, of the Northwestern Memorial Hospital, presented these findings during the...

Off-the-shelf CAR-T regimen safe for advanced lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma

May 31st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

Axitinib prolongs PFS in metastatic adenoid cystic carcinoma
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/{40a4c150-78fc-4a61-ae96-5a8b84f9c6ee}/axitinib-prolongs-pfs-in-metastatic-adenoid-cystic-carcinoma

May 30th, 2020 - Axitinib significantly extended PFS among patients with recurred or metastatic adenoid cystic carcinoma, according to results of a randomized phase 2 study presented during the ASCO20 Virtual Scientific Program.

Early local therapy fails to extend survival in metastatic breast cancer subset
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{fce1cd33-c5fd-4bf8-8336-97281967a80c}/early-local-therapy-fails-to-extend-survival-in-metastatic-breast-cancer-subset

May 31st, 2020 - Early local therapy did not prolong survival among women with de novo metastatic breast cancer and intact primary tumors, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Adjuvant atezolizumab fails to extend DFS in high-risk urothelial carcinoma
https://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{9212b066-b10f-4746-bf88-5ea0cb25b1cf}/adjuvant-atezolizumab-fails-to-extend-dfs-in-high-risk-urothelial-carcinoma

May 31st, 2020 - Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Progressing malignancy linked to higher mortality among patients with cancer and COVID-19
https://www.healio.com/hematology-oncology/practice-management/news/online/{a24c9adf-558c-4ccb-ba95-8c5a2168dcbe}/progressing-malignancy-linked-to-higher-mortality-among-patients-with-cancer-and-covid-19

May 30th, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Children with Down syndrome, ALL at higher risk for poor outcomes
https://www.healio.com/hematology-oncology/leukemia/news/online/{4b3c1cc4-4e4a-462e-b738-7ee6b1d20fd3}/children-with-down-syndrome-all-at-higher-risk-for-poor-outcomes

May 30th, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.

NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research
https://www.healio.com/hematology-oncology/practice-management/news/online/{56279316-24e1-4c34-8527-2538a95b52a9}/nci-director-covid-19-having-profound-effects-on-cancer-outcomes-research

May 29th, 2020 - The oncology community has demonstrated a remarkable ability to adapt amid the COVID-19 pandemic but must be prepared for its long-term effects on cancer care, NCI Director Norman E. “Ned” Sharpless, MD, told ASCO Virtual Scientific Program attendees.

Ramucirumab-gemcitabine combination confers OS benefit in malignant pleural mesothelioma
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{2cadd0d4-adb1-4d44-8ef3-4f1f2b3fa922}/ramucirumab-gemcitabine-combination-confers-os-benefit-in-malignant-pleural-mesothelioma

May 29th, 2020 - The addition of ramucirumab to gemcitabine significantly improved survival among patients with malignant pleural mesothelioma, according to randomized phase 2 study results presented during the ASCO20 Virtual Scientific Program.

Metronomic capecitabine maintenance extends DFS in triple-negative breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{3c339a48-87d5-48c1-ad53-432291e3e553}/metronomic-capecitabine-maintenance-extends-dfs-in-triple-negative-breast-cancer

May 29th, 2020 - A year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer, according to study results presented at ASCO20 Virtual Scientific Program.

HER2-targeted therapy shows antitumor activity in metastatic colorectal cancer
https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/{6840dc0f-5d75-4042-8b28-a618af3ebf99}/her2-targeted-therapy-shows-antitumor-activity-in-metastatic-colorectal-cancer

May 29th, 2020 - Trastuzumab deruxtecan demonstrated durable benefit among patients with HER2-expressing metastatic colorectal cancer, according to findings of the phase 2 DESTINY-CRC01 study presented during the ASCO20 Virtual Scientific Program.

BCMA-targeted CAR-T shows ‘outstanding responses’ in advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{bc81f18d-afd1-42ae-89ae-185ee74b50be}/bcma-targeted-car-t-shows-outstanding-responses-in-advanced-multiple-myeloma

May 30th, 2020 - Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.

First-line doxorubicin plus trabectedin effective, safe for metastatic leiomyosarcoma
https://www.healio.com/hematology-oncology/sarcoma/news/online/{28102d3c-c28b-4f98-950f-daa7db22f27d}/first-line-doxorubicin-plus-trabectedin-effective-safe-for-metastatic-leiomyosarcoma

May 30th, 2020 - Doxorubicin in combination with trabectedin appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program.

Tucatinib combination extends OS in HER2-positive breast cancer with brain metastases
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{ec6da952-b55a-4c7b-bea4-3bd96da58aec}/tucatinib-combination-extends-os-in-her2-positive-breast-cancer-with-brain-metastases

May 29th, 2020 - Tucatinib plus trastuzumab and capecitabine extended OS among patients with brain metastases from HER2-positive breast cancer, according to findings from a randomized phase 3 study presented during the ASCO20 Virtual Scientific Program and simultaneously published in Journal of Clinical Oncology.

Avelumab maintenance extends OS in advanced urothelial carcinoma
https://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{55a121e4-45ae-45ee-a061-27ba8bc78ad8}/avelumab-maintenance-extends-os-in-advanced-urothelial-carcinoma

May 30th, 2020 - Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.

Pyrotinib-capecitabine combination improves outcomes in breast cancer subset
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{290284ab-35d9-4048-81cf-662050787639}/pyrotinib-capecitabine-combination-improves-outcomes-in-breast-cancer-subset

May 29th, 2020 - Pyrotinib plus capecitabine extended PFS compared with lapatinib-capecitabine among certain patients with HER2-positive metastatic breast cancer, according to randomized phase 3 study results presented at ASCO20 Virtual Scientific Program.

Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma
https://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/online/{17cd85c5-d78f-4354-9228-85262589c9eb}/adjuvant-pembrolizumab-confers-durable-rfs-benefit-in-resected-stage-iii-melanoma

May 29th, 2020 - Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.